||
艾立布林显著延长HER2阴性乳腺癌总生存期
近日,一项发表在《eClinicalMedicine》的文章报告了艾立布林用于一线或二线HER2-MBC的III期临床试验结果。与标准一线化疗S-1相比,艾立布林显著延长患者总生存期,两组患者首次临床恶化时间相似,显示出艾立布林作为HER2-MBC一线/二线治疗选择的潜力。CCMTV将其编译成文,以飨读者。
https://pubmed.ncbi.nlm.nih.gov/38785215/
Cancer Med
. 2024 May;13(10):e7295.
doi: 10.1002/cam4.7295.
Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
Affiliations collapse
Affiliations
1Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People's Republic of China.
2Department of Medical Oncology, Head and Neck Cancer Department, West China Hospital, Chengdu, Sichuan Province, People's Republic of China.
PMID: 38785215
PMCID: PMC11117449
DOI: 10.1002/cam4.7295
文献检索与信息分析 艾立布林与乳腺癌
(14)
(7)
(3)
(3)
(2)
(2)
(2)
(1)
(1)
(1)
http://www.pubmedplus.cn/P/SearchQuickResult?wd=0938ae1a-74e5-4eb4-909c-9dde028e63d3
01. | Breast Neoplasms | 164 篇 | 100.000% |
02. | Female | 164 篇 | 100.000% |
03. | Humans | 164 篇 | 100.000% |
04. | Prognosis | 164 篇 | 100.000% |
05. | Receptor, ErbB-2 | 164 篇 | 100.000% |
06. | Receptors, Estrogen | 164 篇 | 100.000% |
07. | Receptors, Progesterone | 164 篇 | 100.000% |
08. | Middle Aged | 138 篇 | 84.146% |
09. | Adult | 120 篇 | 73.171% |
10. | Aged | 112 篇 | 68.293% |
http://www.pubmedplus.cn/P/SearchQuickResult?wd=53c36d2f-3512-436f-bd44-d8f89554a44d
01. | Female | 75 篇 | 74.257% |
02. | Humans | 75 篇 | 74.257% |
03. | Breast Neoplasms | 67 篇 | 66.337% |
04. | Antineoplastic Combined Chemotherapy Protocols | 49 篇 | 48.515% |
05. | Middle Aged | 49 篇 | 48.515% |
06. | Adult | 45 篇 | 44.554% |
07. | Receptor, ErbB-2 | 45 篇 | 44.554% |
08. | Aged | 44 篇 | 43.564% |
09. | Capecitabine | 44 篇 | 43.564% |
10. | Furans | 36 篇 | 35.644% |
http://www.pubmedplus.cn/P/SearchQuickResult?wd=14a0b2e2-570c-48c0-9d6f-afa5ea2fac43
01. | Antineoplastic Agents | 169 篇 | 100.000% |
02. | Breast Neoplasms | 169 篇 | 100.000% |
03. | Humans | 169 篇 | 100.000% |
04. | Female | 164 篇 | 97.041% |
05. | Furans | 145 篇 | 85.799% |
06. | Ketones | 145 篇 | 85.799% |
07. | Middle Aged | 78 篇 | 46.154% |
08. | Aged | 70 篇 | 41.420% |
09. | Treatment Outcome | 70 篇 | 41.420% |
10. | Adult | 64 篇 | 37.870% |
http://www.pubmedplus.cn/P/SearchQuickResult?wd=62cff49e-0fc3-43ce-91d9-0d2daadb0e02
01. | Humans | 72 篇 | 72.727% |
02. | Furans | 69 篇 | 69.697% |
03. | Ketones | 69 篇 | 69.697% |
04. | Female | 64 篇 | 64.646% |
05. | Breast Neoplasms | 58 篇 | 58.586% |
06. | Middle Aged | 34 篇 | 34.343% |
07. | Antineoplastic Agents | 32 篇 | 32.323% |
08. | Adult | 29 篇 | 29.293% |
09. | Aged | 29 篇 | 29.293% |
10. | Antineoplastic Combined Chemotherapy Protocols | 29 篇 | 29.293% |
https://blog.sciencenet.cn/home.php?mod=spacecp&ac=blog&blogid=1447781&op=edit
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-8-24 10:15
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社